1. Home
  2. BYRN vs BSEM Comparison

BYRN vs BSEM Comparison

Compare BYRN & BSEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Byrna Technologies Inc.

BYRN

Byrna Technologies Inc.

N/A

Current Price

$3.87

Market Cap

85.0M

Sector

Miscellaneous

ML Signal

N/A

Logo BioStem Technologies Inc. Common Stock

BSEM

BioStem Technologies Inc. Common Stock

N/A

Current Price

$1.28

Market Cap

76.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BYRN
BSEM
Founded
2005
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.0M
76.9M
IPO Year
2013
2026

Fundamental Metrics

Financial Performance
Metric
BYRN
BSEM
Price
$3.87
$1.28
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $6.33
N/A
AVG Volume (30 Days)
★ 405.7K
226.8K
Earning Date
10-08-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $16,566,295.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.51
$87.68
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 1692.08
N/A
52 Week Low
$3.17
$1.00
52 Week High
$20.69
$5.44

Technical Indicators

Market Signals
Indicator
BYRN
BSEM
Relative Strength Index (RSI) 41.71 38.12
Support Level $3.26 N/A
Resistance Level $5.21 $4.65
Average True Range (ATR) 0.25 0.23
MACD -0.08 0.08
Stochastic Oscillator 25.20 48.39

Price Performance

Historical Comparison
BYRN
BSEM

About BYRN Byrna Technologies Inc.

Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.

About BSEM BioStem Technologies Inc. Common Stock

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.

Share on Social Networks: